Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: A possible peroxidative role for paraoxonase

Journal of Clinical Investigation

Volumn 101, Issue 8, 1998, Pages 1581-1590

  Aviram, Michael ^a,d   Rosenblat, Mira ^a   Bisgaier, Charles L ^b   Newton, Roger S ^b   Primo Parmo, Sergio L ^c   La Du, Bert N ^c  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b PFIZER INC   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Apolipoprotein E deficient mice; HDL; LDL; Lipid peroxidation; Paraoxonase

Indexed keywords

APOLIPOPROTEIN E; ARYLESTERASE; FREE RADICAL; HIGH DENSITY LIPOPROTEIN; LIPID PEROXIDE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL METABOLISM; ENZYME ACTIVATION; HYDROLYSIS; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; RISK FACTOR;

EID: 0032522985     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI1649     Document Type: Article

References (62)

1. LaDu, B.N., S. Adkins, C.L. Kuo, and D. Lipsig. 1993. Studies on human serum paraoxonase/arylesterase. Chem. Biol. Interact. 87:25-34.
2. La Du, B.N. 1996. Structural and functional diversity of paraoxonases [news]. Nat. Med. 2:1186-1187.
3. Mackness, M.I., B. Mackness, P.N. Durrington, P.W. Connelly, and R.A. Hegele. 1996. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr. Opin. Lipidol. 7:69-76.
4. Nevin, D.N., A. Zambon, C.E. Furlong, R.J. Richter, R. Humbert, J.E. Hokanson, and J.D. Brunzell. 1996. Paraoxonase genotypes, lipoprotein lipase activity, and HDL. Arterioscler. Thromb. Vasc. Biol. 16:1243-1249.
5. McElveen, J., M.I. Mackness, C.M. Colley, T. Peard, S. Warner, and C.H. Walker. 1986. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin. Chem. 32:671-673.
6. Mackness, M.I., D. Harty, D. Bhatnagar, P.M. Winocour, S. Arrol, M. Ishola, and P.N. Durrington. 1991. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis. 86:193-199.
7. Abbott, C.A., M.I. Mackness, S. Kumar, A.J. Boulton, and P.N. Durrington. 1995. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler. Thromb. Vasc. Biol. 15:1812-1818.
8. Banka, C.L. 1996. High density lipoprotein and lipoprotein oxidation. Curr. Opin. Lipidol. 7:139-142.
9. Mackness, M.I., and P.N. Durrington. 1995. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis. 115:243-253.
10. Mackness, M.I., S. Arrol, C. Abbott, and P.N. Durrington. 1993. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 104:129-135.
11. Mackness, M.I., C. Abbott, S. Arrol, and P.N. Durrington. 1993. The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem. J. 294:829-834.
12. Mackness, M.I., S. Arrol, and P.N. Durrington. 1991. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286: 152-154.
13. Hayek, T., J. Oiknine, G. Dankner, J.G. Brook, and M. Aviram. 1995. HDL apolipoprotein A-I attenuates oxidative modification of low density lipoprotein: studies in transgenic mice. Eur. J. Clin. Chem. Clin. Biochem. 33:721-725.
14. Navab, M., J.A. Berliner, A.D. Watson, S.Y. Hama, M.C. Territo, A.J. Lusis, D.M. Shih, B.J. Van Lenten, J.S. Frank, L.L. Demer, et al. 1996. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler. Thromb. Vasc. Biol. 16:831-842.
15. Watson, A.D., J.A. Berliner, S.Y. Hama, B.N. La Du, K.F. Faull, A.M. Fogelman, and M. Navab. 1995. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96:2882-2891.
16. Watson, A.D., M. Navab, S.Y. Hama, A. Sevanian, S.M. Prescott, D.M. Stafforini, T.M. McIntyre, B.N. Du, A.M. Fogelman, and J.A. Berliner. 1995. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J. Clin. Invest. 95:774-782.
17. Bowry, V.W., K.K. Stanley, and R. Stocker. 1992. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc. Natl. Acad. Sci. USA. 89:10316-10320.
18. Hahn, M., and M.T. Subbiah. 1994. Significant association of lipid peroxidation products with high density lipoproteins. Biochem. Mol. Biol. Int. 33: 699-704.
19. Christison, J.K., K.A. Rye, and R. Stocker. 1995. Exchange of oxidized cholesteryl linoleate between LDL and HDL mediated by cholesteryl ester transfer protein. J. Lipid Res. 36:2017-2026.
20. Nagano, Y., H. Arai, and T. Kita. 1991. High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification. Proc. Natl. Acad Sci. USA. 88:6457-6461.
21. Morel, D.W. 1994. Reduced cholesterol efflux to mildly oxidized high density lipoprotein. Biochem. Biophvs. Res. Commun. 200:408-416.
22. Aviram, M. 1983. Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hyperlipoproteinemic patients. Biochem. Med. 30:111-118.
23. Esterbauer, H., G. Striegl, H. Puhl, and M. Rotheneder. 1989. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Rad. Res. Commun. 6:67-75.
24. Buege, J.A., and S.D. Aust. 1978. Microsomal lipid peroxidation. Methods Enzymol. 52:302-310.
25. El Saadani, M., H. Esterbauer, M. el Sayed, M. Goher, A.Y. Nassar, and G. Jurgens. 1989. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J. Lipid Res. 30:627-630.
26. Vaya, J., P.A. Belinky, and M. Aviram. 1997. Antioxidant constituents from licorice roots: isolation, structure elucidation and antioxidative capacity toward LDL oxidation. Free Rad. Biol. Med. 23:302-313.
27. Aviram, M., E.L. Bierman, and J.F. Oram. 1989. High density lipoprotein stimulates sterol translocation between intracellular and plasma membrane pools in human monocyte-derived macrophages. J Lipid Res. 30:65-76.
28. Kuo, C.L., and B.N. La Du. 1995. Comparison of purified human and rabbit serum paraoxonases. Drug Metab. Dispos. 23:935-944.
29. Gan, K.N., A. Smolen, H.W. Eckerson, and B.N. La Du. 1991. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab. Dispos. 19:100-106.
30. Eckerson, H.W., J. Romson, C. Wyte, and B.N. La Du. 1983. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am. J. Hum. Genet. 35:214-227.
31. Kitchen, B.J., C.J. Masters, and D.J. Winzor. 1973. Effects of lipid removal on the molecular size and kinetic properties of bovine plasma arylesterase. Biochem. J. 135:93-99.
32. Chen, C.H., and J.J. Albers. 1982. Characterization of proteoliposomes containing apoprotein A-I: a new substrate for the measurement of lecithin: cholesterol acyltransferase activity. J. Lipid Res. 23:680-691.
33. Aviram, M., I. Maor, S. Keidar, T. Hayek, J. Oiknine, Y. Bar El, Z. Adler, V. Kertzman, and S. Milo. 1995. Lesioned low density lipoprotein in atherosclerotic apolipoprotein E-deficient transgenic mice and in humans is oxidized and aggregated. Biochem. Biophys. Res. Commun. 216:501-513.
34. Hayek, T., J. Oiknine, J.G. Brook, and M. Aviram. 1994. Increased plasma and lipoprotein lipid peroxidation in apo E-deficient mice. Biochem. Biophys. Res. Commun. 201:1567-1574.
35. Hayek, T., B. Fuhrman, J. Vaya, M. Rosenblat, P. Belinki, R. Coleman, A. Elis, and M. Aviram. 1997. Reduced progression of atherosclerosis in the apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin, or catechin, is associated with reduced susceptibility of LDL to oxidation and to aggregation. Arterioscler. Throm. Vasc. Biol. 17:2744-2752.
36. Aviram, M. 1993. Modified forms of low density lipoprotein and atherosclerosis. Atherosclerosis. 98:1-9.
37. Garin, M.C., R.W. James, P. Dussoix, H. Blanche, P. Passa, P. Froguel, and J. Ruiz. 1997. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J. Clin. Invest. 99:62-66.
38. Mackness, M.I., S. Arrol, B. Mackness, and P.N. Durrington. 1997. Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation [letter]. Lancet. 349: 851-852.
39. Zhang, S.H., R.L. Reddick, B. Burkey, and N. Maeda. 1994. Diet-induced atherosclerosis in mice heterozygous and homozygous for apolipoprotein E gene disruption. J. Clin. Invest. 94:937-945.
40. Reddick, R.L., S.H. Zhang, and N. Maeda. 1994. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler. Thromb. 14:141-147.
41. Palinski, W., V.A. Ord, A.S. Plump, J.L. Breslow, D. Steinberg, and J.L. Witztum. 1994. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler. Thromb. 14:605-616.
42. Palinski, W., S. Horkko, E. Miller, U.P. Steinbrecher, H.C. Powell, L.K. Curtiss, and J.L. Witztum. 1996. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J. Clin. Invest. 98:800-814.
43. Shih, D.M., L. Gu, S. Hama, Y.R. Xia, M. Navab, A.M. Fogelman, and A.J. Lusis. 1996. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J. Clin. Invest. 97:1630-1639.
44. Navab, M., S. Hama Levy, B.J. Van Lenten, G.C. Fonarow, C.J. Cardinez, L.W. Castellani, M.L. Brennan, A.J. Lusis, and A.M. Fogelman. 1997. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J. Clin. Invest. 99:2005-2019.
45. Lynch, S.M., and B. Frei. 1993. Mechanisms of copper- and iron-dependent oxidative modification of human low density lipoprotein. J. Lipid Res. 34: 1745-1753.
46. Aviram, M. 1996. Interaction of oxidized low density lipoprotein with macrophages in atherosclerosis, and the antiatherogenicity of antioxidants. Eur. J. Clin. Chem. Clin. Biochem. 34:599-608.
47. Steinberg, D., S. Parthasarathy, T.E. Carew, J.C. Khoo, and J.L. Witztum. 1989. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity [see comments]. N. Engl. J. Med. 320:915-924.
48. Jialal, I., and S.M. Grundy. 1992. Effect of dietary supplementation with alpha-tocopherol on the oxidative modification of low density lipoprotein. J. Lipid Res. 33:899-906.
49. Parthasarathy, S., S.G. Young, J.L. Witztum, R.C. Pittman, and D. Steinberg. 1986. Probucol inhibits oxidative modification of low density lipoprotein. J. Clin. Invest. 77:641-644.
50. de Whalley, C.V., S.M. Rankin, J.R. Hoult, W. Jessup, and D.S. Leake. 1990. Flavonoids inhibit the oxidative modification of low density lipoproteins by macrophages. Biochem. Pharmacol. 39:1743-1750.
51. Levy, Y., M. Kaplan, A. Ben Amotz, and M. Aviram. 1996. Effect of dietary supplementation of beta-carotene on human monocyte-macrophage-mediated oxidation of low density lipoprotein. Isr. J. Med. Sci. 32:473-478.
52. Fuhrman, B., A. Lavy, and M. Aviram. 1995. Consumption of red wine with meals reduces the susceptibility of human plasma and low-density lipoprotein to lipid peroxidation. Am. J. Clin. Nutr. 61:549-554.
53. Fuhrman, B., S. Buch, J. Vaya, P.A. Belinky, R. Coleman, T. Hayek, and M. Aviram. 1997. Licorice extract and its major polyphenol glabridin protect low-density lipoprotein against lipid peroxidation: in vitro and ex vivo studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am. J. Clin, Nutr. 66:267-275.
54. Mitchinson, M.J., R.Y. Ball, K.L. Carpenter, and J.H. Enright. 1990. Macrophages and ceroid in human atherosclerosis. Eur. Heart J. 11:116-121.
55. Gordon, D.J., J. Knoke, J.L. Probstfield, R. Superko, and H.A. Tyroler. 1986. High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial. Circulation. 74:1217-1225.
56. Miller, N.E. 1987. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am. Heart J. 113:589-597.
57. Oram, J.F., and S. Yokoyama. 1996. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J. Lipid Res. 37:2473-2491.
58. Reichl, D., and N.E. Miller. 1989. Pathophysiology of reverse cholesterol transport. Insights from inherited disorders of lipoprotein metabolism. Arteriosclerosis. 9:785-797.
59. Sorenson, R.C., S.L. Primo Parmo, C.L. Kuo, S. Adkins, O. Lockridge, and B.N. La Du. 1995. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc. Natl. Acad. Sci. USA. 92:7187-7191.
60. Aviram, M., S. Billecke, R. Sorenson, C. Bisgaier, R. Newton, M. Rosenblot, J. Erogul, C. Hsu, C. Dunlop, and B.N. La Du. 1998. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different than that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler. Thromb. Vasc. Biol. In press.
61. Hazen, S.L., F.F. Hsu, K. Duffin, and J.W. Heinecke. 1996. Molecular chlorine generated by the myeloperoxidase-hydrogen peroxide-chloride system of phagocytes converts low density lipoprotein cholesterol into a family of chlorinated sterols. J. Biol. Chem. 271:23080-2308.
62. Wilkins, G.M., and D.S. Leae. 1994. The effects of free radical scavengers on the oxidation of low-density lipoproteins by macrophages. Biochim. Biophys. Acta. 1215:250-258.